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Abstract
Background: Several reports have suggested that raised intracranial pressure (ICP) is a major
contributor to death among children with cerebral malaria. Mannitol, an osmotic diuretic,
effectively lowers ICP and is used to treat post-traumatic raised ICP. It is not clear whether
intravenous mannitol given to children with cerebral malaria improves clinical outcome. The
objective of this study was to determine the effect of mannitol as adjunct therapy on the clinical
outcome of children with cerebral malaria.
Methods: This randomized double-blind placebo controlled clinical trial was carried out at the
Emergency Paediatric ward of Mulago Hospital, Uganda's national referral and teaching hospital.
One hundred and fifty six children aged 6 to 60 months with cerebral malaria were randomized to
either one dose of mannitol 1 g/kg or placebo, in addition to intravenous quinine. Main outcome
measures included coma recovery time; time to sit unsupported, begin oral intake; duration of
hospitalization; death and adverse effects.
Results: Time to regain consciousness (p = 0.11), sit unsupported (p = 0.81), time to start oral
intake (p = 0.13) and total coma duration (p = 0.07) were similar in both groups. There was no
significant difference in the mortality between the placebo (13/80 or 16.3%) and mannitol (10/76
or 13.2%) groups: RR = 1.2 (CI 0.5–2.7). No adverse effects were observed after administration of
mannitol.
Conclusion: Mannitol had no significant impact on clinical outcome of cerebral malaria. It is
difficult to recommend intravenous mannitol as adjunct therapy for childhood cerebral malaria.
Clinical registration number: ClinicalTrials.gov ID: NCT00113854
Background
Cerebral malaria is one of the most severe and life threat-
ening complications of Plasmodium falciparum infection
accounting for high mortality [1-3]. Several studies have
shown evidence of raised intracranial pressure in children
with cerebral malaria and this may be associated with
poor outcome[4,5].
Published: 24 October 2007
Malaria Journal 2007, 6:138 doi:10.1186/1475-2875-6-138
Received: 4 July 2007
Accepted: 24 October 2007
This article is available from: http://www.malariajournal.com/content/6/1/138
© 2007 Namutangula et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Malaria Journal 2007, 6:138 http://www.malariajournal.com/content/6/1/138
Page 2 of 6
(page number not for citation purposes)
Mannitol, an osmotic diuretic lowers intracranial pressure
by creating an osmotic gradient that draws water from
brain parenchyma into the brain capillaries. It also slows
production of cerebral spinal fluid, which further reduces
intracranial pressure [6]. Although recommended and
used to treat post-traumatic comatose patients[6,7] it is
not yet recommended in cerebral malaria due to lack of
conclusive evidence. No randomized or quasi-rand-
omized controlled trials support or refute the use of man-
nitol as adjunct treatment for cerebral malaria. A
randomized trial was performed to determine the effect of
mannitol as adjunct therapy on the clinical outcome of
cerebral malaria in children.
Methods
Patients were enrolled from October 2004 to May 2005 in
the Paediatric Emergency ward of Mulago Hospital,
Uganda's national referral and teaching hospital.
Selection criteria
Children aged between six months and five years, who ful-
filled the WHO case definition of cerebral malaria
(unrousable coma lasting more than 30 minutes after a
seizure with peripheral asexual P. falciparum parasitaemia
and absence of other causes of coma) and those whose
caretakers gave informed consent were included. Those
children who had been sedated within two hours before
admission; those with overt signs of pulmonary conges-
tion, heart failure, a history of renal disease or had not
passed urine within 24 hours before admission were
excluded.
Randomization and blinding
The caretakers and investigators were blinded to group
assignments. Study numbers were computer generated
and sent to the manufacturer for labeling of the drug bot-
tles. Randomization was done in blocks of variable sizes
(4–10) to ensure equal distribution in each group.
Patients were randomized to receive either mannitol or
placebo in addition to treatment for severe malaria (intra-
venous quinine). Both mannitol and placebo were
administered as intravenous infusions over 20 minutes.
One of the investigators (BN) and an assistant, both of
whom were blinded to the treatment, carried out observa-
tions.
Treatment
All patients received intravenous quinine dihydrochloride
10 mg salt/kg body weight in 10 mls/kg of 5% dextrose,
which was infused over 2–4 hours and repeated every
eight hours till the patient regained consciousness. Qui-
nine sulphate was then given orally (10 mg salt/kg) every
eight hours till a total of seven days was reached.
Patients in the mannitol group received 5 ml/kg of 20% (1
g/kg) intravenous mannitol over 20 minutes, while those
in the placebo group received 5 ml/kg of normal saline
over 20 min in addition to intravenous quinine. The pla-
cebo bottles contained 100 ml of normal saline while the
mannitol bottles contained 100 ml of 20% mannitol.
Supportive measures included control of seizures,
hypoglycaemia, severe anaemia and fever.
Feeding was through a naso-gastric tube until the child
was able to take orally. Patients were followed daily until
discharge, death or up to day 7. The level of consciousness
was assessed three hourly using the Blantyre coma scale
until full consciousness was regained.
Laboratory tests
These included cerebral spinal fluid analysis, complete
blood count, liver function tests and blood sugar (day 0),
renal function tests (day 0 repeated on day 3), and periph-
eral blood smear for malaria parasites (day 0, day 3 and
day 7). Malaria parasite density was determined by
Giemsa-stained thick films and counted per 200 white
blood cells; the results were expressed as parasites per µL
assuming a total white blood cell count of 8,000× 106/L.
Main outcome measures
These included: time to regain consciousness (from the
start of treatment till the Blantyre coma scale reached 5);
time to sit unsupported ;time to start oral feeds; and dura-
tion of hospital stay (from start of treatment to discharge).
Sample size and statistical issues
A sample size of 78 patients in each group for 90% power
and 95% confidence interval was calculated, with an
assumption that 41% of the children would have regained
consciousness by the first 24 hours[8]. An assumption was
also made that this would increase to 66% with mannitol.
Analysis was by intention to treat. Differences in the two
groups were compared using student t tests, the Mann
Whitney U test (where appropriate); the log rank tests for
continuous outcomes, and the chi squared test and odds
ratios and risk ratios for categorical variables.
Ethical issues
Permission to conduct the study was obtained from the
Uganda National Council for Science and Technology,
Makerere University Medical School and Mulago hospital
Research and Ethics committees. Parents gave informed
consent for the children's participation in the study.
Results
Two hundred and forty seven children were screened for
eligibility and 156 were enrolled and treated. Seventy-six
patients were randomly assigned to receive mannitol
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characteristics were comparable in both groups (Table 1).
For example the commonest symptoms were fever
(98.7%) and convulsion (98.7%). The mean number of
convulsions on admission was 3.8 (SD 2.8) in the placebo
group and 4.1 (SD 2.5) in the mannitol group
Generally there was no significant difference in the clini-
cal outcomes (Table 2) between the two treatment groups.
Kaplan Meier survival analysis revealed similar trends in
the two treatment groups, with the log rank tests showing
no significant difference (Figures 2, 3, 4).
Adverse effects
There was no hypersensitivity reaction or vomiting noted
in any of the children after receiving mannitol. There was
no significant change in the renal function, pulse, or
blood pressure.
Twenty two children died and one was lost to follow up.
Since the analysis was by intention to treat, this patient
was assigned the worst possible outcome (death). This
brought the number of deaths to 23 (14.7% overall mor-
tality); that is 10 (13.2%: CI 7.1–22.8%) in the mannitol
group and 13 (16.3%: CI 9.6–26.0%) in the placebo
group. The difference in mortlity between the two groups
was not statistically significant (RR = 1.2 (CI 0.5–2.7).
Post-mortem examination was done on 6 children whose
caretakers consented. Five children had signs of anoxia
and cerebral oedema while the sixth child had signs of
acute tubular necrosis.
Discussion
The aim of this study was to determine the effect of man-
nitol as adjunct therapy on the clinical outcome of chil-
dren with cerebral malaria. The differences in clinical
outcomes between the mannitol and placebo groups were
generally not significant.
Time to regain consciousness
Median time to regain consciousness was shorter in the
mannitol group (18.9 hours) than in the placebo group
(20.5 hours), but this was not statistically significant. A
few studies have assessed time to regain consciousness
using other adjunct therapies such as iron chelation [9]
and dexamethasone [10]. When intravenous mannitol is
compared to these interventions [9,10], the time to regain
consciousness is much shorter. In the current study, the
rate of recovery from coma among patients receiving man-
nitol was 1.6 times that of patients on placebo.
Failure to demonstrate a significant effect may be due to
the fact that coma in cerebral malaria is a result of multi-
ple factors of which cerebral oedema [11] and increased
Table 1: Baseline clinical characteristic of the 156 patients with cerebral malaria in both treatment arms on admission.
Variable Placebo
N = 80
Mannitol
N = 76
P value
Female 42(52.5%) 34(44.7%) 0.33
Fever 79(98.8) 76 (100%) 0.33
Convulsions 79(98.8%) 75(98.7%) 0.97
Duration of coma 7.0 (IQR3.5–12.0) 6.0 (5.0–12.0) 0.79
Blantyre coma score 1/5 13(16.2%) 10(13.2%) 0.59
Abnormal fundoscopic changesa 28(35.0%)) 16(21.1%) 0.53
Papilloedema 3(3.8%) 5(6.6%) 0.42
Sodium – mmol/l (SD) 133.8 (4.2) 130.9 (14.8) 0.09
Hb – g/dl (SD) 7.1 (1.8) 7.1 (1.9) 0.98
Parasite density/µL (IQR) 37000(5390–115760) 58860(12390–284590) 0.05
IQR Inter Quartile Range
aAbnormal fundoscopic changes (congested retinal veins, blurred disc margins, papilloema, retinal haemorrhages) indicative of raised intracranial 
pressure
Trial profile Figure 1
Trial profile.
Cerebral malaria
247 children
Excluded:
Age<6 or >60 months=59
Died before recruitment =32
156 recruited
76 randomly assigned
to mannitol
80 randomly assigned
to placebo
67 survived 66 survived 13 died 9 died
1l ost to followMalaria Journal 2007, 6:138 http://www.malariajournal.com/content/6/1/138
Page 4 of 6
(page number not for citation purposes)
intracranial pressure [12] are just a part. Unfortunately,
intracranial pressure was not measured, so it is not possi-
ble to confirm whether it was a major contributor to
coma. Although the diagnosis of malaria is straight for-
ward, not all patients fulfilling the WHO definition of cer-
ebral malaria have the disease especially in areas where P.
falciparum parasitaemia is often asymptomatic. It is possi-
ble that imprecise diagnosis may mask the benefits of an
intervention such as mannitol.
It is possible that the dose (1 g/kg) of mannitol used was
small hence the lack of a significant difference in time to
regain consciousness. Mannitol doses ranging from 0.25
g/kg to 2.5 g/kg have been used in some studies [13,14].
Bolus doses of 0.25/kg, 0.5 g/kg, > 1.0 g/kg reduce intrac-
ranial pressure in patients with head injury by 25%, 78%
and 98% respectively [13]. In Kenya, Newton et al [5] gave
0.5–1 g/kg of intravenous mannitol to children with cere-
bral malaria, while in Ghana, mannitol was given at a
higher dose (1 g/kg) 8 hourly[15]. Both studies, showed a
positive effect of mannitol on coma recovery for children
who received it. However, these studies were not designed
to assess the effect of mannitol as adjunct therapy in cere-
bral malaria.
Time to begin oral intake
The median time taken to begin oral intake was shorter in
the mannitol group (34.0 hours) than in the placebo
group (40.0 hours), but the difference was not statistically
significant (Mann Whitney-U Test).
Time to sit unsupported
There was no significant difference between the two
groups in the time taken to sit unsupported. The children
in the mannitol group regained consciousness earlier than
those in the placebo group hence were expected to sit
unsupported earlier than those in the placebo group.
Kaplan Meier curve for time to begin oral intake (hours) for  the children with cerebral malaria in the two treatment arms Figure 3
Kaplan Meier curve for time to begin oral intake (hours) for 
the children with cerebral malaria in the two treatment arms.
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Table 2: Outcome of 133 children who survived with cerebral malaria in the two groups
Outcome Placebo(N = 67)
Median (IQR)
Mannitol(N = 66)
Median (IQR))
P value*
Time [hours] to regain consciousness 20.5(14.1–53.4) 18.9(10.0–38.0) 0.11
Time [hours] to oral intake 40.0(23.3–66.3) 34.0(19.0–61.0) 0.13
Time [hours] to sit unsupported 49.0(33.0–69.8) 49.0(29.0–74.0) 0.81
Total coma duration 46.3(33.5–81.4) 43.0(22.9–70.0) 0.07
CI = Confidence Interval
* Mann-Whitney U-test
Kaplan Meir survival curve for time to regain consciousness  (hours) by treatment group among the children with cerebral  malaria Figure 2
Kaplan Meir survival curve for time to regain consciousness 
(hours) by treatment group among the children with cerebral 
malaria.
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Mortality
The difference in mortality between the two groups was
not significant but was comparable to ranges of 7–17%
reported in other Uganda[3,16] and African[1,9,17] stud-
ies.
Although this study was not powered to detect differences
in mortality, the fact that fewer children died in the man-
nitol group compared to the placebo group and that the
mortality was within the ranges seen in most African stud-
ies, may be an indication that mannitol is not deleterious.
However this needs to be tested with a larger sample size.
Only six of the 23 children who died had post-mortem
examinations done as consent was declined in the
remaining children. All but one of these six children had
succumbed to cerebral malaria as evidenced by cerebral
vascular congestion, petechial hemorrhages in the brain
and a histological picture consistent with malarial tropho-
zoite invasion of the RBCs in the cerebral vasculature.
These findings are similar to those found in other studies
[3,8]. One child had evidence of acute renal failure and it
is very likely that the acute tubular necrosis, which
resulted in his death, was a result of malaria. This child
was from the placebo group, hence mannitol could not
have caused his renal impairment. Renal impairment is
common in severe malaria[18] and though it rarely
progresses into frank renal failure, it is associated with
poor outcome. Factors, which significantly predicted mor-
tality, included; multiple convulsions (> 5), deep coma
(BCS of <2/5), leucocytosis and abnormal fundoscopic
findings (papilloedema, retinal haemorrhages and retinal
vein congestion), which are similar to those, described in
earlier studies [1,19,20].
Adverse effects
Apart from death, no major adverse effects were identi-
fied. Deaths in the mannitol group were probably due to
the cerebral malaria and not the mannitol since the mor-
tality was within the ranges of other studies and was com-
parable with the number of deaths in the placebo group.
Mannitol (1 g/kg) did not significantly affect renal func-
tion in the children with cerebral malaria. There was also
no significant difference in the blood pressure and pulse
changes between the two groups. Other adverse effects
such as exacerbation of heart failure and pulmonary
oedema were not observed.
Conclusion
In conclusion, mannitol did not significantly reduce time
taken to regain consciousness, sit unsupported, or mortal-
ity. It is difficult to recommend intravenous mannitol as
adjunct therapy for childhood cerebral malaria.
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